

Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum- based chemotherapy (terminated appraisal)

Technology appraisal guidance

Published: 29 May 2025

www.nice.org.uk/guidance/ta1068

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of tislelizumab (Tevimbra) for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its evidence submission.

Information

If NHS organisations wish to consider tislelizumab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7048-3